A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Once or Twice Daily for 12 Weeks in Subjects With Moderate to Severe Inflammatory Facial Acne Vulgaris
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs VB 1953 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Vyome Therapeutics
- 30 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2019 Status changed from not yet recruiting to recruiting.
- 01 Apr 2019 Status changed from planning to not yet recruiting.